Baxter International announced last week that it has agreed to buy a privately held drugmaker whose primary product is a medicine to combat irregular heartbeat. Deerfield, Ill.-based Baxter plans to pay $170 million at closing and up to $168 million in the future based on sales, for Pennsylvania-based Prism Pharmaceuticals, according to a news release.
Baxter to buy Prism Pharmaceuticals
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.